MELDEPLIKTIG HANDEL BLANT PRIMÆRINNSIDER

DiaGenic opplyste 26.november om gjennomført emisjon. Den 25. november er det gjennomført meldepliktig handel blant primærinnsider i DiaGenic ASA. Håkon Sæterøy, som er arbeidende styreleder i DiaGenic ASA, har fått minimumstildelingen på 155.000 aksjer i emisjonen til kurs NOK 2,75 per aksje. Sæterøy har dermed økt eksponeringen i selskapet og har etter emisjonen til sammen 1.396.478 aksjer i direkte og indirekte eie. Kontaktperson: Dr Med Erik Christensen, administrerende direktør Telefon: +47 95939918 e-mail: erik.christensen@diagenic.com

Om oss

DiaGenic ASA is an innovative Norwegian life sciences company founded in 1998 and listed on the Oslo Stock Exchange. DiaGenic develops patient-friendly tests for the early diagnosis of devastating diseases where early intervention is crucial for successful treatment. DiaGenic’s patented method is based on identifying disease-specific gene signatures from easily available sample material such as blood. DiaGenic's strategy is to work with research and technology partners to develop a pipeline of assays for commercialisation by major diagnostics companies. Currently DiaGenic’s first two tests for the early detection of breast cancer and Alzheimer’s disease are on track to enter extensive clinical trials during 2007. The company has been awarded substantial development grants as part of the Norwegian Research Council’s FUGE programme.

Abonner